Recently, the state organized the joint drug procurement office to issue a notice. The selection results of the Sixth Batch of national centralized drug procurement (insulin special) will be implemented in May 2022. The specific implementation date shall be subject to the notice issued by all localities. Up to now, the 6 purchase of drug concentration volume has been carried out by the state organization. The average price of the selected drugs is 53%, covering the mainstream drugs such as hypertension, diabetes, hyperlipidemia, chronic hepatitis B and other chronic diseases and common diseases. In recent years, the reform of centralized procurement of drugs and high-value medical consumables has been continuously promoted. At the executive meeting of the State Council held on the 10th, it was pointed out that the market-oriented mechanism for centralized procurement of drugs and high-value medical consumables effectively squeezed the falsely high medical prices. By the end of last year, a total of 260 billion yuan had been saved for medical insurance and patients. At the same time, it also promoted pharmaceutical enterprises to devote more energy to product R & D and improve quality. The reform of centralized procurement with volume based on the principle of "integration of bidding and procurement and linking volume with price" is having an important impact on the pharmaceutical industry. The relevant person in charge of the National Medical Insurance Bureau said that by reasonably determining the procurement rules and centralized procurement, enterprises can further promote fair competition, reduce the cost of intermediate links, open the space for price reduction, cut off the grey interest chain of pharmaceutical circulation and use links, purify the field of pharmaceutical circulation and guide prices to return to a reasonable level. For the next step of centralized purchase of drugs and high-value medical consumables, the national level also pointed out the direction, including: continue to promote the centralized purchase of drugs at the national level, focusing on chronic diseases and common diseases, and carry out provincial or inter provincial alliance procurement of drugs outside the national centralized purchase; Gradually expand the coverage of centralized procurement of high-value medical consumables, and carry out centralized procurement of orthopaedic consumables, drug balloons and dental implants concerned by the masses at the national and provincial levels respectively; Ensure the long-term stable supply of selected drugs and consumables, strengthen supervision, and ensure that the price of selected products does not degrade. Medical institutions should give reasonable priority to the use of the selected products. We will implement the policy of retaining the balance of centralized medical insurance funds, promote the reform of the salary system, reasonably increase the income of medical personnel, and better mobilize their enthusiasm. Jiang Changshong, director of the price bidding and procurement office of the National Institute of medical security, believes that the state organizes centralized drug procurement to effectively purify the industry ecology, improve the intensive scale, promote enterprise upgrading and innovation, improve the drug use level of patients, improve the efficiency of fund use, and promote the continuous deepening of medical reform. According to the national medical insurance administration, during the "14th five year plan" period, we will strengthen the centralized volume procurement of drugs and medical consumables, promote the centralized volume procurement to become the leading mode, carry out the national centralized volume procurement of drugs in a normalized and institutionalized manner, and continue to expand the scope of centralized volume procurement of high-value medical consumables. (Xinhua News Agency)